Balss, J
Thiede, C
Bochtler, T
Okun, J G
Saadati, M
Benner, A
Pusch, S
Ehninger, G
Schaich, M
Ho, A D
von Deimling, A
Krämer, A
Heilig, C E
Article History
Received: 15 October 2015
Revised: 23 October 2015
Accepted: 2 November 2015
First Online: 19 November 2015
Competing interests
: JB: DKFZ (patent/intellectual property), Bayer Healthcare (research funding). CT: AgenDix Diagnostics GmbH (stock/other ownership), Bayer (research funding). TB: TEVA (travel, accomodations). SP: DKFZ (patent/intellectual property). GE: Celgene (research funding), GEMoaB Monoclonals (patent/intellectual property, stock/other ownership), Rhön-Klinikum AG (leadership role, stock/other ownership), Cellex GmbH (stock/other ownership), GEMoaB Monoclonals (stock/other ownership), AgenDix Diagnostics GmbH (stock/other ownership), Novartis (travel, accomodations, expenses). AD: Dianova/Roche (patent/intellectual property). AK: Novartis (consulting/advisory role), Roche (research funding), Bayer (research funding), DKFZ (patent/intellectual property), TEVA (travel, accomodations). CEH: Gilead, TEVA, Pharmamar, Shire, MSD (travel, accomodations). The remaining authors declare no conflict of interest.